Amedisys — Q2 2021 Earnings Presentation
25 slides from Amedisys's earnings presentation, Aug 4, 2021
Slide 1: Amedisys Second Quarter 2021 Earnings Call Supplemental Slides
Amedisys Second Quarter 2021 Earnings Call Supplemental Slides August 5th, 2021 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus and progress made during Q2’21 Home Health*: Total same store admissions +20%, Total same store volume +12% Hospice: Admissions +2%, ADC -3% Personal Care: Billable hours / quarter -5%. Personal Care Network drove ~$1.0 revenue to Home Health and Hospi
Slide 4: Highlights and Summary Financial Results (Adjusted): 2Q 2021
Highlights and Summary Financial Results (Adjusted): 2Q 2021(1) Home Health total same store volume +12%, total same store admissions +20%; Hospice same store admissions +2% Amedisys Consolidated Revenue Growth: +15% EBITDA: $84M (+26%) EBITDA Margin: 15.0% (+130 bps) EPS: $1.69 (+26%) 2Q’21 Net deb
Slide 5: Our Revenue Sources: 2Q'21
Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care, majority of which range from 95% - 100% of Medicare rates Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per
Slide 6: Home Health and Hospice Segment (Adjusted) – 2Q 2021
Home Health and Hospice Segment (Adjusted) – 2Q 2021(1) Revenue per Episode up 6.0% (one additional month of sequestration benefit and 2021 rate increase +1.9%) Y/Y CPV up $6.95 (+7.5%, primarily due to an increase in contractor utilization, new hire pay, health costs and raises) Visits per Episode
Slide 7: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A increased $20 million; however, total G&A as a percentage of revenue decreased 50 basis points Year over year G&A increase due to the AseraCare acquisition (~$5M = Hospice segment), a slowdown in prior year spend rela
Slide 8: Cost per Visit Components
Components 2Q’20 1Q’21 2Q’21 YoY Variance Detail Initiatives Salaries $63.03 $64.54 $65.02 $1.99 YoY and Sequential increases due to higher fixed new hire pay due to the timing of hires YoY increase also due to planned wage increases Staffing mix optimization, productivity and scheduling improvement
Slide 9: Driving Top Line Growth
Driving Top Line Growth Home Health total volume growth remains strong. Hospice admissions and ADC, as well as Personal Care billable hours lagging due to prolonged COVID-19 impacts, staffing challenges specifically Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter
Slide 10: Industry Leading Quality Scores
Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 Release Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric OCT 19 Release JAN 20
Slide 11: Hospice Quality
Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022
Slide 12: Debt and Liquidity Metrics
Debt and Liquidity Metrics Net leverage ~0.5x. Proforma for the Contessa acquisition and under the new Credit Facility, Net leverage ~1.4x Net debt defined as total debt outstanding ($191.8M) less cash ($33.3M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITD
Slide 13: Credit Facility Amendment – Key Terms
Credit Facility Amendment – Key Terms Existing Facility New Facility Size and Structure $725 million Senior Secured Credit Facility $550 million revolving credit facility $175 million Term Loan A $1,000 million Senior Secured Credit Facility $550 million revolving credit facility $450 million Term L
Slide 14: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) 2020 includes benefits of payroll tax deferral (COVID-19 relief). Total payroll tax deferral of ~$55.4M due back as ~$27.7M in December 2021 and ~$27.7M in December 2022. Free cash flow defined as cash flow from operations less routine capital expenditures and requ
Slide 15: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021 and June 30, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP fin
Slide 16: Contessa
Contessa
Slide 17: AMED + Contessa create a differentiated in-home care organization
AMED + Contessa create a truly differentiated, tech-enabled, risk-bearing, higher-acuity, end-to-end, in-home care organization Aging-in-Place Highest quality, data driven, end to end, value base-d care Merger Consideration AMED acquired Contessa for $250 million purchase price funded via cash on ha
Slide 18: Contessa and Amedisys Current Geographic Reach
Contessa Home Recovery Amedisys Home Health Amedisys Hospice Contessa and Amedisys Current Geographic Reach Multiple high quality hospital system relationships. Growth opportunity with established Contessa health system relationships by adding hospitals, and through an additional pipeline of active
Slide 19: Strategic Rationale
Strategic Rationale Mutually beneficial acquisition creates accelerated revenue growth opportunities for both Contessa and Amedisys, enhanced payor innovation platform, more robust data capabilities, and new hospital relationships with highly synergistic cross-selling opportunities Expansion of Home
Slide 20: Combination Expands Total Addressable Market (TAM)
Combination Expands Total Addressable Market (TAM) Contessa’s capabilities help to significantly expand the TAM of the in-home care services market for Amedisys Notes: Home Health, Hospice and Infusion represent all payor markets Primary Care at Home (PCP) represents top 8% acuity of MA members SNF
Slide 21: Significant opportunity to scale current portfolio across markets
Significant opportunity to scale current portfolio diversified across various sized markets Economics of Markets Near Maturity Note: Market tiering based on population density and health system footprint (i.e., Tier 1 markets are more urban while Tier 3 markets are more rural). Run-rate of trailing
Slide 22: 2021 Guidance
2021 Guidance
Slide 23: Amedisys 2021 Updated Guidance
Amedisys 2021 Updated Guidance Updated Revenue, EBITDA and EPS guidance ranges for FY 2021 reflect COVID impact and include Contessa and VNA acquisitions ($M except for EPS) Original Guidance Updated Guidance Post Q1 (Sequestration Only) AMED Core Performance Impact of Contessa and VNA Updated AMED
Slide 24: Environmental, Social, Governance (E.S.G.) Considerations
Environmental, Social, Governance (E.S.G.) Considerations
Slide 25: Environmental, Social, Governance (E.S.G.) Considerations
Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental, Social, Governance Environmental Amedisys is dedicated to the sustainability of our business and the communities in which we serve Environmental health has a str